Mechanisms of Inactivation of T Cells by HSV
Mechanisms of Inactivation of T Cells by HSV
批准号:
7216524
负责人:
KEITH R JEROME
金额:
$38.71万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-08-01 至 2008-07-31
中文摘要
描述(由申请人提供):疱疹病毒已经进化出多种机制来应对宿主免疫反应带来的威胁。其中一种我们称之为“失活”,即T细胞与单纯疱疹病毒感染的细胞发生物理接触后,通过T细胞受体(TcR)对刺激做出反应的能力出现严重缺陷。灭活的T细胞不执行颗粒介导的细胞毒性,也不会在TcR刺激后分泌细胞因子。我们最近证实了失活T细胞中的两种信号缺陷,一种与HSP90的磷酸化有关,另一种与T细胞活化连接体(LAT)的去磷酸化有关。然而,单纯疱疹病毒感染细胞诱导失活的机制尚不清楚。为此,我们提出以下建议。具体目标确定有缺陷的HSV颗粒是否需要传递病毒蛋白才能发生失活。根据我们的初步数据,最可能的假设是,失活是通过缺乏DNA的缺陷病毒颗粒向T细胞传递蛋白质而发生的。为了评估这一点,我们将使用转染了由大量包装在缺陷颗粒内的病毒反激活子驱动的报告结构的T细胞,以确定病毒蛋白进入T细胞是否与失活相关。接下来,我们将使用纯化的颗粒来确定这些颗粒的结合和融合是否足以诱导失活。具体目标2。确定灭活所需和足够的病毒蛋白。我们将使用HSV被膜和包膜蛋白的缺失突变体来确定哪些病毒蛋白是发生失活所必需的。一旦确定了必要的蛋白质,我们将在T细胞中单独或联合表达这些蛋白质,以确定是否有任何蛋白质足以介导失活。具体目标3。确定灭活刺激的细胞靶。为了开始了解导致HSP90磷酸化和LAT去磷酸化的细胞内事件,我们将确定失活信号的初始细胞靶点。我们将通过鉴定与目标2中发现的病毒蛋白相互作用的细胞蛋白,以及通过评估失活对已知与HSP90和LAT相互作用或修饰的细胞蛋白的影响来做到这一点。阐明HSV灭活T细胞的机制将为T细胞的调控提供新的见解,并可能为药理学操作提供靶点。
英文摘要
DESCRIPTION (provided by applicant): The herpesviruses have evolved a variety of mechanisms to deal with the threat posed by the host immune response. In one of these, which we refer to as "inactivation", T cells that come in physical contact with HSV-infected cells develop a profound defect in their ability to respond to stimulation via the T cell receptor (TcR). Inactivated T cells do not perform granule-mediated cytotoxity, nor do they secrete cytokines after TcR stimulation. We have recently demonstrated two signaling defects within inactivated T cells, one related to the phosphorylation of HSP90, and one related to the dephosphoryation of linker for activation of T cells (LAT). However, the mechanism by which HSV-infected cells induce inactivation is not clear. To address this, we propose the following. Specific Aim 1. Determine whether delivery of viral protein by defective HSV particles is necessary for inactivation to occur. Based on our preliminary data, the most likely hypothesis is that inactivation occurs via delivery of protein to the T cells by defective viral particles lacking DNA. To evaluate this, we will use T cells transfected with a reporter construct driven by a viral transactivator abundantly packaged within the defective particles, to determine whether delivery of viral protein into T cells correlates with inactivation. Next, we will use purified particles to determine whether binding and fusion of these particles are sufficient to induce inactivation. Specific Aim 2. Determine the viral proteins necessary and sufficient for inactivation. We will use deletion mutants of HSV tegument and envelope proteins to determine which viral proteins are necessary for inactivation to occur. Once the necessary proteins are identified, we will express these proteins individually and in combination in T cells to determine whether any are sufficient to mediate inactivation. Specific Aim 3. Determine the cellular target for the inactivating stimulus. To begin to understand the intracellular events leading to phosphorylation of HSP90 and dephosphorylation of LAT, we will determine the initial cellular target for the inactivating signal. We will do this by identifying the cellular proteins interacting with the viral proteins found to be sufficient in aim 2, and by evaluating the effect of inactivation on cellular proteins known to interact with or modify HSP90 and LAT. The elucidaton of the mechanism by which HSV inactivates T cells will provide new insight into the regulation of T cells, and may suggest targets for pharmacologic manipulation.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Endonuclease-mediated disruption of latent HSV as curative therapy
-
批准号:10182099
-
项目类别:
-
资助金额:$44.0万
-
财政年份:2018
-
负责人:KEITH R JEROME
-
依托单位:
Endonuclease-mediated disruption of latent HSV as curative therapy
-
批准号:10155424
-
项目类别:
-
资助金额:$28.28万
-
财政年份:2018
-
负责人:KEITH R JEROME
-
依托单位:
Endonuclease-mediated disruption of latent HSV as curative therapy
-
批准号:9597105
-
项目类别:
-
资助金额:$45.01万
-
财政年份:2018
-
负责人:KEITH R JEROME
-
依托单位:
Endonuclease-mediated disruption of latent HSV as curative therapy
-
批准号:10405036
-
项目类别:
-
资助金额:$43.77万
-
财政年份:2018
-
负责人:KEITH R JEROME
-
依托单位:
Endonuclease-mediated disruption of latent HSV as curative therapy
-
批准号:9927580
-
项目类别:
-
资助金额:$43.78万
-
财政年份:2018
-
负责人:KEITH R JEROME
-
依托单位:
Endonuclease-mediated disruption of latent HSV as curative therapy
-
批准号:10593355
-
项目类别:
-
资助金额:$15.5万
-
财政年份:2018
-
负责人:KEITH R JEROME
-
依托单位:
In vivo inactivation of latent HSV by endonuclease-mediated mutagenesis
-
批准号:9199202
-
项目类别:
-
资助金额:$22.0万
-
财政年份:2016
-
负责人:KEITH R JEROME
-
依托单位:
Cell and Gene Therapy for HIV Cure
-
批准号:9191169
-
项目类别:
-
资助金额:$471.5万
-
财政年份:2016
-
负责人:KEITH R JEROME
-
依托单位:
Cell and Gene Therapy for HIV Cure
-
批准号:10593375
-
项目类别:
-
资助金额:$40.73万
-
财政年份:2016
-
负责人:KEITH R JEROME
-
依托单位:
In vivo inactivation of latent HSV by endonuclease-mediated mutagenesis
-
批准号:9035463
-
项目类别:
-
资助金额:$26.4万
-
财政年份:2016
-
负责人:KEITH R JEROME
-
依托单位:
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection
-
批准号:8691703
-
项目类别:
-
资助金额:$406.88万
-
财政年份:2011
-
负责人:KEITH R JEROME
-
依托单位:
Targeted Disruption of Integrated SHIV by Engineered Homing Endonucleases
-
批准号:8202339
-
项目类别:
-
资助金额:$58.68万
-
财政年份:2011
-
负责人:KEITH R JEROME
-
依托单位:
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection
-
批准号:8876542
-
项目类别:
-
资助金额:$437.13万
-
财政年份:2011
-
负责人:KEITH R JEROME
-
依托单位:
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection
-
批准号:8185379
-
项目类别:
-
资助金额:$393.21万
-
财政年份:2011
-
负责人:KEITH R JEROME
-
依托单位:
Administrative Core
-
批准号:8202353
-
项目类别:
-
资助金额:$24.45万
-
财政年份:2011
-
负责人:KEITH R JEROME
-
依托单位:
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection
-
批准号:8299007
-
项目类别:
-
资助金额:$403.38万
-
财政年份:2011
-
负责人:KEITH R JEROME
-
依托单位:
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection
-
批准号:8497599
-
项目类别:
-
资助金额:$437.51万
-
财政年份:2011
-
负责人:KEITH R JEROME
-
依托单位:
Inactivation of CTL by HSV-infected cells
-
批准号:6811469
-
项目类别:
-
资助金额:$25.95万
-
财政年份:2004
-
负责人:KEITH R JEROME
-
依托单位:
Inactivation of CTL by HSV-infected cells
-
批准号:6929273
-
项目类别:
-
资助金额:$21.63万
-
财政年份:2004
-
负责人:KEITH R JEROME
-
依托单位:
Inhibition of CTL killing by HSV
-
批准号:6732169
-
项目类别:
-
资助金额:$25.95万
-
财政年份:2001
-
负责人:KEITH R JEROME
-
依托单位:
国内基金
海外基金
登录
查看更多内容
SOD1介导星形胶质细胞活化调控hNSC移植细胞存活的机制研究
-
批准号:82372136
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:付雪梅
-
依托单位:
PCBP1和PCBP2调控cGAS的相变和酶活的机制研究
-
批准号:32370928
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:孙钦秒
-
依托单位:
利用密码子扩展技术对细胞焦亡中gasdermin家族蛋白行为进行特异性荧光标记与成像研究
-
批准号:32200598
-
项目类别:青年科学基金项目(C类)
-
资助金额:20.0万元
-
批准年份:2022
-
负责人:祝融峰
-
依托单位:
自噬外泌体的鉴定及形成机制研究
-
批准号:32100544
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2021
-
负责人:高瑛
-
依托单位:
褪黑素促进MCL-1抑制剂诱导白血病细胞凋亡的分子机制研究
-
批准号:32100607
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:叶开琴
-
依托单位:
CEP290在纤毛发生起始过程中的作用及机制研究
-
批准号:32070692
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:卫青
-
依托单位:
高尔基体结构蛋白GRASP55参与膜融合的功能鉴定和调控机制研究
-
批准号:32070693
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:张晓妍
-
依托单位:
热应激通过MAPK信号通路介导Vγ9Vδ2 T细胞抗肿瘤活性调控作用研究
-
批准号:32000534
-
项目类别:青年科学基金项目
-
资助金额:16.0万元
-
批准年份:2020
-
负责人:林丽
-
依托单位:
LMD-2 蛋白对秀丽线虫溶酶体相关细胞器生成与动态调控机制的研究
-
批准号:31960143
-
项目类别:地区科学基金项目
-
资助金额:42.0万元
-
批准年份:2019
-
负责人:李婧琳
-
依托单位:
未闭合自噬体与溶酶体融合的鉴定及意义
-
批准号:91954125
-
项目类别:重大研究计划
-
资助金额:65.0万元
-
批准年份:2019
-
负责人:梁永恒
-
依托单位: